Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies. Its portfolio consists of royalties on approximately 35 marketed therapies and 10 development-stage product candidates that address various therapeutic areas, such as rare disease, cancer, neurology, infectious disease, hematology, and diabetes. The company was founded in 1996 and is based in New York, New York.

Royalty Pharma plc

Adalvo is a global pharmaceutical company with a purpose to make a difference for patients around the world, driven by a smart collaboration network and a commitment to deliver quality differentiated products and services to its partners. Self-described as being 'always on target.'

Adalvo

Royalty Pharma is the world's largest buyer of biopharmaceutical royalties and a funder of innovation in life sciences.

Metric
Company Name	Royalty Pharma plc	Adalvo
Symbol	RPRX
MSH ID	COM:ROYALTYPHARMA	COM:ADALVO
Market	STOCKS	PRIVATE
Sector	Healthcare	Healthcare & Health Services
Industry	Biotechnology	Pharmaceuticals
Country	US	UK
Stage
Employee Count	75
Website	royaltypharma.com	adalvo.com
LinkedIn
Founders

Metric
Market Cap	11.63B
Enterprise Value
Monthly Web Traffic
Web Traffic Growth
Valuation
Raised Capital

Metric
Revenue	2.35B
Revenue (LTM)
Revenue (NTM)
Gross Profit	2.35B
EBITDA	1.49B
Operating Income	1.49B
Net Income	1.13B
EPS	2.54
Diluted EPS	2.53
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin	0.73
Operating Profit Margin	0.63
EBITDA Margin	0.63
Net Profit Margin	0.48
Return on Equity	0.18
Return on Assets	0.07
Return on Capital Employed	0.09

COM:ROYALTYPHARMA

Royalty Pharma

Last Close

26.40

22/11 21:00

Market Cap

11.63B

Beta: -

Volume Today

2.46M

Avg: -

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio	410.95
P/B Ratio	2.03
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio	5.83
EV Multiple	7.86

Metric
Days Sales Outstanding	5.95
Days Payables Outstanding	877.22
Days Inventory Outstanding
Operating Cycle	126.21
Cash Conversion Cycle	117.14
Asset Turnover	0.14

Metric
Operating Cash Flow	3.03B
Free Cash Flow	916.16M
Cash Flow to Debt	0.49
Operating Cash Flow/Sales	1.27
Free Cash Flow Yield	0.17

Metric
Cash & Equivalents	477.01M
Accounts Receivable	1.07M
Inventory
Goodwill
Debt to Capitalization	0.54
Debt to Assets	0.39
Current Ratio	13.51
Quick Ratio	12.52

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue	0.00
R&D to Revenue	0.04
SG&A to Revenue	0.11